Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma

Despite advances in the treatment of cancers through surgical procedures and new pharmaceuticals, the treatment of hepatocellular carcinoma (HCC) remains challenging as reflected by low survival rates. The PI3K/Akt/mTOR pathway is an important signaling mechanism that regulates the cell cycle, proli...

Full description

Bibliographic Details
Main Authors: Eun Jin Sun, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane, Lionel Hebbard
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Biomedicines
Subjects:
hepatocellular carcinoma
HCC
Akt
mTOR
PI3K
clinical trials
Online Access:https://www.mdpi.com/2227-9059/9/11/1639

Internet

https://www.mdpi.com/2227-9059/9/11/1639

Similar Items